SEARCH

SEARCH BY CITATION

References

  • Abu-Amero, K. K., B. Milcarek, and T. M. Bosley. 2009. GSTM1 and GSTT1 deletion genotypes in various spontaneous optic neuropathies in Arabs. Br. J. Ophthalmol. 93:11011104.
  • Arand, M., R. Muhlbauer, J. Hengstler, E. Jager, J. Fuchs, L. Winkler, and F. Oesch. 1996. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal. Biochem. 236:184186.
  • Barahmani, N., S. Carpentieri, X. N. Li, T. Wang, Y. Cao, L. Howe, L. Kilburn, M. Chintagumpala, C. Lau, and M. F. Okcu. 2009. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro. Oncol. 11:292300.
  • Beghi, E., and M. L. Monticelli, (IGPSG) IGPSG. 1995. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology 45:18321836.
  • Benhamou, S., M. Reinikainen, C. Bouchardy, P. Dayer, and A. Hirvonen. 1998. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 58:52915293.
  • Chang, C. M., C. W. Yu, K. Y. Fong, S. Y. Leung, T. W. Tsin, Y. L. Yu, T. F. Cheung, and S. Y. Chan. 1993. N-hexane neuropathy in offset printers. J. Neurol. Neurosurg. Psychiatry 56:538542.
  • De Palma, G., F. D. Dick, S. Calzetti, N. W. Scott, G. J. Prescott, A. Osborne, N. Haites, P. Mozzoni, A. Negrotti, A. Scaglioni, et al . 2010. A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions. Mov. Disord. 25:912919.
  • Dick, F. D., G. De Palma, A. Ahmadi, A. Osborne, N. W. Scott, G. J. Prescott, J. Bennett, S. Semple, S. Dick, P. Mozzoni, et al . 2007. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Environ. Med. 64:673680.
  • Feldman, R. G. 1999. n-Hexane and Methyl n-Butyl Keton. In: occupational and environmental neurotoxicology . Lippincott-Raven, Philadelphia , PA . Pp. 290317.
  • Gandhi, S., and N. W. Wood. 2010. Genome-wide association studies: the key to unlocking neurodegeneration? Nat. Neurosci. 13:789794.
  • Garte, S., L. Gaspari, A. K. Alexandrie, C. Ambrosone, H. Autrup, J. L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, et al . 2001. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10:12391248.
  • Ginsberg, G., S. Smolenski, D. Hattis, K. Z. Guyton, D. O. Johns, and B. Sonawane. 2009. Genetic polymorphism in glutathione transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity. J. Toxicol. Environ. Health B: Crit. Rev. 12:389439.
  • Griffin, J. W., and D. F. Watson. 1988. Axonal transport in neurological disease. Ann. Neurol. 23:313.
  • Guengerich, F. P. 1982. Epoxide hydrolase: properties and metabolic roles. Rev. Biochem. Toxicol. 4:430.
  • Hassett, C., L. Aicher, J. S. Sidhu, and C. J. Omiecinski. 1994. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants.[erratum appears in Hum Mol Genet 1994 Jul;3(7):1214]. Hum. Mol. Genet. 3:421428.
  • Hayes, J. D., and R. C. Strange. 2000. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154166.
  • Ishikawa, K., T. Funayama, H. Ohde, Y. Inagaki, and Y. Mashima. 2005. Genetic variants of TP53 and EPHX1 in Leber's hereditary optic neuropathy and their relationship to age at onset. Jpn. J. Ophthalmol. 49:121126.
  • Lancaster, J. M., H. A. Brownlee, D. A. Bell, P. A. Futreal, J. R. Marks, A. Berchuck, R. W. Wiseman, and J. A. Taylor. 1996. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol. Carcinog. 17:160162.
  • Lecomte, T., B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot. 2006. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12:30503056.
  • Lindh, J., M. Tondel, A. Österberg, and M. Vrethem. 2005. Cryptogenic polyneuropathy: clinical and neurophysiological findings. J. Peripher. Nerv. Syst. 10:3137.
  • Mannervik, B. 1985. The isoenzymes of glutathione transferase. Adv. Enzymol. Relat. Areas Mol. Biol. 57:357417.
  • Martyn, C. N., and R. A. Hughes. 1997. Epidemiology of peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry 62:310318.
  • Oesch, F. 1973. Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3:305340.
  • Omiecinski, C. J., L. Aicher, R. Holubkov, and H. Checkoway. 1993. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 3:150158.
  • Rebbeck, T. R.. 1997. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6:733743.
  • Shatunov, A., K. Mok, S. Newhouse, M. E. Weale, B. Smith, C. Vance, L. Johnson, J. H. Veldink, M. A. van Es, L. H. van den Berg, et al . 2010. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 9:986994.
  • Smith, C. A. D., and D. J. Harrison. 1997. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630633.
  • Söderkvist, P., A. Ahmadi, A. Akerback, O. Axelson, U. Flodin. 1996. Glutathione S-transferase M1 null genotype as a risk modifier for solvent-induced chronic toxic encephalopathy. Scandinavian Journal of Work, Environment & Health 22:360363.
  • Spencer, P. S., and H. H. Schaumburg. 2000. Experimental and clinical neurotoxicology . Oxford Univ. Press, Oxford .
  • Spencer, P. S., M. I. Sabri, H. H. Schaumburg, and C. L. Moore. 1979. Does a defect of energy metabolism in the nerve fiber underlie axonal degeneration in polyneuropathies? Ann. Neurol. 5:501507.
  • Tesfaye, S., N. Chaturvedi, S. E. Eaton, J. D. Ward, C. Manes, C. Ionescu-Tirgoviste, D. R. Witte, J. H. Fuller. 2005. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352:341350.
  • Teunissen, L. L., H. Franssen, J. H. Wokke, Y. van der Graaf, W. H. Linssen, J. D. Banga, D. M. Laman, and N. C. Notermans. 2002. Is cardiovascular disease a risk factor in the development of axonal polyneuropathy? J. Neurol. Neurosurg. Psychiatry 72:590595.
  • Timbrell, J. 2000. Factors affecting toxic responses: metabolism. Pp. 65110 in T Francis, ed. Principles of biochemical toxicology . Taylor & Francis Ltd., London .
  • Tondel, M., J. Lindh, P. Jonsson, M. Vrethem, and B. Persson. 2006. Occupational determinants of cryptogenic polyneuropathy. Neuroepidemiology 26:187194.
  • Xu, S., Y. Wang, B. Roe, and W. R. Pearson. 1998. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. J. Biol. Chem. 273:35173527.
  • Zhang, Y., Q. Liu, H. Duan, J. Cheng, S. Jiang, X. Huang, S. Leng, F. He, and Y. Zheng. 2006. Association between metabolic gene polymorphisms and susceptibility to peripheral nerve damage in workers exposed to n-hexane: a preliminary study. Biomarkers 11:6169.